Epitalon Regulatory Status: What the July 2026 FDA Advisory Committee Vote Means
By Evergreen Editorial · 7/25/2026
Medically reviewed by Dr. Casey Greene, PharmD, FMCP, Senior Director of Clinical Informatics
Epitalon Regulatory Status: What the July 2026 FDA Advisory Committee Vote Means
Is Epitalon legal to compound right now?
Not yet. Compounding Epitalon is not currently legal or authorized, and here's exactly where things stand. On July 24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend Epitalon for the list of bulk drug substances licensed pharmacies can legally compound. The vote is a recommendation only. The FDA reviewed Epitalon specifically for insomnia. Formal FDA rulemaking must happen before compounding becomes legal. Evergreen Telehealth will update this page as that regulatory process moves forward.
CURRENT REGULATORY STATUS — Last updated: July 24, 2026 PCAC voted to recommend Epitalon for inclusion on the FDA's Section 503A Bulks List. This is a recommendation to the FDA, not a legal change. Compounding Epitalon is not currently authorized under Section 503A. FDA rulemaking to formally add Epitalon to the list has not started. Section 503A of the FD&C Act, together with FDA's general rulemaking authority under section 701(a) of the FD&C Act (21 U.S.C. 371(a)), is the legal authority FDA would use. FDA would first publish a Notice of Proposed Rulemaking under 21 CFR 216.23, followed by a public comment period of typically 60 to 90 days, then review and respond to comments before issuing a final rule, which typically takes effect 30 days after publication. Those phases each have an established time frame. The one variable that cannot be predicted is how long FDA itself takes internally to draft the proposed rule and respond to comments.
What is Epitalon?
Epitalon is a synthetic tetrapeptide studied primarily for its effects on the pineal gland and for a proposed role in activating telomerase, an enzyme involved in maintaining the protective caps on chromosomes. The FDA's Pharmacy Compounding Advisory Committee reviewed Epitalon specifically for insomnia. Inclusion on the Bulks List, if it happens, does not evaluate specific use. The FDA may still limit the compoundable form or route.
Most available data on Epitalon comes from a limited number of research groups, which is a notable evidence gap on its own. FDA reviewers also flagged a specific safety concern worth carrying onto this page: nonclinical data showed Epitalon activates telomerase and lengthens telomeres in human cells, and while some researchers have proposed anti-aging and tumor-suppressing effects from this, the FDA noted that longer telomeres are also associated with increased cancer risk, and that available studies were too short and narrow to characterize Epitalon's carcinogenic potential either way. Epitalon also received an orphan drug designation for retinitis pigmentosa in 2010 that was later withdrawn.
Human clinical trial data on Epitalon remains limited. This page describes the peptide's regulatory status. It does not make claims about safety or effectiveness beyond what the FDA committee reviewed.
| Question | Answer |
|---|---|
| Did PCAC vote to recommend Epitalon? | Yes, on July 24, 2026. |
| Does this vote mean Epitalon is safe and effective? | The vote reflects the committee's assessment of Epitalon against the compounding statute's four-factor test (21 CFR 216.23(c)): historical use, characterization, safety, and effectiveness for compounding purposes. That is a different and lower evidentiary bar than full FDA drug approval, which Epitalon has not received for any use. |
| Is Epitalon legal to compound today? | No. |
| Has the FDA approved Epitalon as a drug? | No. This vote does not constitute FDA approval of Epitalon for any use. |
| Does this vote bind the FDA? | No. PCAC is advisory. The FDA is not required to follow its recommendation. |
What happens next?
The FDA reviews the PCAC recommendation and decides whether to proceed with rulemaking. If it proceeds, Section 503A of the FD&C Act and FDA's general rulemaking authority under section 701(a) (21 U.S.C. 371(a)) is the legal basis for adding Epitalon to the Bulks List. Some phases of that process have known, established time frames. The variable that cannot be predicted is how long FDA itself takes internally to draft the proposed rule and respond to public comments.
| Stage | Known time frame |
|---|---|
| PCAC advisory vote | Complete. Voted to recommend inclusion. |
| FDA decision on whether to pursue rulemaking, and drafting of the Notice of Proposed Rulemaking (21 CFR 216.23) | Not predictable; depends on FDA's internal process. |
| Public comment period | Typically 60 to 90 days once the proposed rule publishes. |
| FDA review and response to comments, and drafting of the final rule | Not predictable; depends on FDA's internal process. |
| Final rule effective date | Typically 30 days after the final rule publishes. |
| Legal compounding under Section 503A | Not currently authorized. |
How do I access Epitalon through a licensed pharmacy?
You cannot legally access compounded Epitalon through any licensed 503A pharmacy today, because it is not currently authorized for compounding. Evergreen Telehealth does not compound, dispense, or facilitate access to Epitalon while it remains outside the 503A Bulks List.
If the FDA completes rulemaking and adds Epitalon to the 503A Bulks List, Evergreen's existing licensed pathway would apply the same physician evaluation and pharmacist oversight standards it uses for every substance it offers through its partner pharmacies.
| Access path | Legal status today | Practitioner and quality oversight |
|---|---|---|
| Licensed 503A compounding pharmacy (Evergreen's pathway, once available) | Not available until FDA rulemaking is complete | Physician evaluation, licensed pharmacist compounding, fulfillment through top 1% national PCAB/ASHP-accredited partner pharmacies |
| Unregulated online "research chemical" sellers | Outside the legal compounding framework regardless of the PCAC vote | No standardized purity testing, no prescription requirement, no pharmacist oversight |
PCAB/ASHP-accredited facility standards reflect Evergreen's own partner-pharmacy requirement. They are not a mandatory condition of any FDA final rule, if and when one is issued.
Common questions about Epitalon right now
Can I still buy Epitalon online today? You can find it sold online as a "research chemical," but that market sits outside the licensed pharmacy system. It carries no standardized purity testing, no prescription requirement, and no pharmacist oversight. The July 24 vote does not change that. We would rather you have the full picture than a partial one.
Does the FDA committee's vote mean Epitalon has been proven to work, or to be safe? No. The vote is a recommendation about whether Epitalon belongs on a list pharmacies are allowed to compound from. The vote does reflect the committee's assessment of Epitalon against the compounding statute's four-factor test, which weighs historical use, characterization, safety, and effectiveness for compounding purposes. That is a different and lower evidentiary bar than full FDA drug approval, which Epitalon has not received for any use. The FDA's own scientific staff had recommended against inclusion, and specifically flagged an unresolved question about long-term cancer risk that current research has not settled either way.
Will my doctor be able to prescribe compounded Epitalon soon? Not yet. The FDA still has to decide whether to move forward with formal rulemaking, then run a public comment period, then issue a final rule. That process has not started. The comment period and final-rule effective date have known time frames, typically 60 to 90 days and 30 days respectively, but how long FDA itself takes to draft the rule and respond to comments is not predictable.
What's actually different now that the committee voted yes? Nothing changes today for what pharmacies can legally compound. What changed is that the FDA now has an advisory recommendation on record. The FDA still has to act on it.
How will I know when this actually changes? We will keep this page updated as the FDA's process moves forward, so you do not have to track it yourself. Check the status box at the top of this page any time for the most current information.
Medically reviewed by Dr. Casey Greene, PharmD, FMCP, Director of Consultative Services, Evergreen Telehealth, on July 24, 2026.
Regulatory disclosures
This page describes a regulatory process in progress. It is not medical advice. It does not claim that Epitalon is safe or effective for any use beyond what the FDA committee reviewed. It does not claim or imply FDA approval of Epitalon. This page will be updated as the FDA's rulemaking process moves forward.